Mandate

Vinge advises Calliditas Therapeutics in connection with Asahi Kasei Corporation’s public takeover offer

On 28 May 2024, Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas Therapeutics AB (publ) (”Calliditas Therapeutics”) to acquire all shares and American Depositary Shares (each representing two shares) in Calliditas Therapeutics.

Calliditas Therapeutics is a biopharma company listed on Nasdaq Stockholm and on the Nasdaq Global Select Market in the US focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. The total value of the offer amounts to approximately SEK 11,164 million, based on the total number of outstanding shares in Calliditas Therapeutics. Vinge advises Calliditas Therapeutics.

Vinge’s team has mainly consisted of Dain Hård Nevonen, Linnéa Sellström, William Kåge and Benjamin Vafaeian (Capital Markets and Public M&A) and Daniel Wendelsson (FDI).

Related

Vinge advises Baseload Capital in connection with an investment from Google

Vinge has advised Baseload Capital Holding AB in connection with securing an investment from Google.
April 16, 2025

Vinge advises Acrinova in connection with the sale of properties

Vinge advises Acrinova AB (publ) in connection with its sale of properties with an underlying property value of SEK 1.4 billion.
April 15, 2025

Vinge has advised Visa in connection with its investment in Mynt AB

Vinge has advised Visa in connection with its investment in the Swedish fintech company Mynt AB ("Mynt"). The investment, which is part of Mynt's announced Series B funding round, underscores Visa's commitment to supporting innovative fintech solutions and improving payment experiences for businesses across Europe.
April 14, 2025